Baxter shares flu vaccine results

DEERFIELD - Baxter International Inc., in conjunction with DynPort Vaccine Co. LLC, Thursday presented Phase III study data measuring the clinical efficacy for Preflucel, a trivalent seasonal influenza candidate vaccine. Preflucel is made using Baxter's Vero cell culture platform and does not contain an adjuvant or preservatives. The data were presented at the International Congress on Infectious Disease. The Phase III clinical study found a 78 percent overall protection rate against culture-confirmed influenza from influenza strains that matched those in the vaccine and a 71 percent rate of prevention of influenza from all circulating strains.